Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data. Through proprietary bioinformatics pipelines and AI algorithms, Tempus delivers interpretive reports that highlight actionable mutations, potential biomarkers and relevant clinical trials. In addition to oncology applications, the platform is designed to support research across immuno-oncology, hematology and other therapeutic areas, helping pharmaceutical and biotechnology partners accelerate drug discovery and development.
Founded in 2015 by entrepreneur Eric Lefkofsky, who serves as chairman and chief executive officer, Tempus is headquartered in Chicago with additional laboratory and research facilities across the United States. Under Lefkofsky’s leadership, the company has grown its dataset to include hundreds of thousands of de-identified patient records, establishing one of the industry’s largest repositories of real-world evidence. Tempus collaborates with academic medical centers, regional health systems and community oncology practices to expand access to genomic testing and AI-enabled insights.
Through strategic partnerships and a continuous investment in technology, Tempus AI (NASDAQ:TEM)ms to democratize access to precision medicine and improve patient outcomes on a global scale. Its services are utilized by healthcare providers seeking to tailor treatment plans, by researchers conducting retrospective analyses, and by life sciences organizations pursuing novel therapeutic targets, underscoring Tempus’s role at the intersection of data science and clinical innovation.
